Court Rules RA Capital and Avilar Misappropriated Yale Trade Secret, Awards $4M to Biohaven
BHVN sits 92% above its 52-week low of $7.48.
Summary
A federal court confirmed that RA Capital and Avilar Therapeutics misappropriated a Yale trade secret, awarding $4 million to Biohaven and Yale. This is a legal victory for Biohaven, validating its intellectual property position and potentially deterring future infringement. The award is modest relative to Biohaven's market cap but carries strategic weight in protecting its pipeline. The ruling may strengthen Biohaven's negotiating position in any related disputes or licensing discussions. No prior news in the timeline covered this development, making it a fresh, material event for investors.
At the time of this announcement, BHVN was trading at $14.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.